Eli Lilly and Co Q2 2022 Earnings Call Transcript - Thomson StreetEvents

Eli Lilly and Co Q2 2022 Earnings Call Transcript

Eli Lilly and Co Q2 2022 Earnings Call Transcript - Thomson StreetEvents
Eli Lilly and Co Q2 2022 Earnings Call Transcript
Published Aug 04, 2022
26 pages (16562 words) — Published Aug 04, 2022
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of LLY.N earnings conference call or presentation 4-Aug-22 2:00pm GMT

  
Brief Excerpt:

...Operator Ladies and gentlemen, thank you for standing by. Welcome to the Lilly Q2 2022 Earnings Conference Call. (Operator Instructions) And as a reminder, your conference is being recorded. I would now like to turn the conference over to your host, Kevin Hern, Vice President of Investor Relations. Please go ahead. Kevin Hern ...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Eli Lilly and Co
Ticker
LLY.N
Time
2:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Kerry Ann Holford - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Two questions, please. Firstly, on price, you have clearly cited lower realized prices for a number of drugs this quarter, particularly in the U.S. And I'm wondering if you can speak specifically to how that's evolving in the GLP-1 market. Any particular step-up on Trulicity rebates since the Mounjaro launch? What are your expectations there going forward? This is a trend, these higher rebates from negative channel mix as noted by your competitor in their results call yesterday. So interested in getting your perspectives here. And then a quick question for Anat. When do you anticipate having greater clarity on the possible repeal of the 2017 Tax Act?

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : Kevin, thanks for all the great work. On business development, you had 2 deals announced today. Can you just give us your updated thoughts on the areas of interest, the deal size? And then just what your -- what's the feedback you're getting from potential targets on their willingness to transact given the market backdrop? And then secondly, just on donanemab, what's your latest thinking or have you had any interactions with CMS with regards to how a single successful Phase III trial would be viewed in the context of reimbursement?

Table Of Contents

Eli Lilly and Co Q3 2022 Earnings Call Summary – 2022-11-01 – US$ 54.00 – Edited Brief of LLY.N earnings conference call or presentation 1-Nov-22 1:00pm GMT

Eli Lilly and Co Q3 2022 Earnings Call Transcript – 2022-11-01 – US$ 54.00 – Edited Transcript of LLY.N earnings conference call or presentation 1-Nov-22 1:00pm GMT

Eli Lilly and Co at Morgan Stanley Global Healthcare Conference Transcript – 2022-09-13 – US$ 54.00 – Edited Transcript of LLY.N presentation 13-Sep-22 3:10pm GMT

Eli Lilly and Co at Citi BioPharma Conference Transcript – 2022-09-07 – US$ 54.00 – Edited Transcript of LLY.N presentation 7-Sep-22 7:30pm GMT

Eli Lilly and Co Q2 2022 Earnings Call Summary – 2022-08-04 – US$ 54.00 – Edited Brief of LLY.N earnings conference call or presentation 4-Aug-22 2:00pm GMT

Eli Lilly and Co at Goldman Sachs Global Healthcare Conference Transcript – 2022-06-14 – US$ 54.00 – Edited Transcript of LLY.N presentation 14-Jun-22 5:40pm GMT

Eli Lilly and Co Diabetes & Obesity Update at ADA Call Transcript – 2022-06-07 – US$ 54.00 – Edited Transcript of LLY.N conference call or presentation 7-Jun-22 3:30pm GMT

Eli Lilly and Co at UBS Global Healthcare Conference Transcript – 2022-05-24 – US$ 54.00 – Edited Transcript of LLY.N presentation 24-May-22 12:30pm GMT

Eli Lilly and Co at Bank of America Healthcare Conference Transcript – 2022-05-10 – US$ 54.00 – Edited Transcript of LLY.N presentation 10-May-22 11:40pm GMT

Eli Lilly and Co Q1 2022 Earnings Call Summary – 2022-04-28 – US$ 54.00 – Edited Brief of LLY.N earnings conference call or presentation 28-Apr-22 1:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Eli Lilly and Co Q2 2022 Earnings Call Transcript" Aug 04, 2022. Alacra Store. May 13, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q2-2022-Eli-Lilly-and-Co-Earnings-Call-T15014217>
  
APA:
Thomson StreetEvents. (2022). Eli Lilly and Co Q2 2022 Earnings Call Transcript Aug 04, 2022. New York, NY: Alacra Store. Retrieved May 13, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q2-2022-Eli-Lilly-and-Co-Earnings-Call-T15014217>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.